Quinolones A Systematic Quest
|
|
- Mildred Randall
- 6 years ago
- Views:
Transcription
1 Quinolones A Systematic Quest David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical School
2 Timeline of Quinolone Development orris S, Mandell GL in Andriole V (ed). The Quinolones 1988
3 George Y. Lesher, Ph.D
4 Surprise Beginnings H 3 C O C 2 H 5 alidixic Acid COOH
5 Quinolones The irst Decade (Childhood) 1962 Discovery of alidixic Acid as antibacterial byproduct of chloroquine synthesis (Lesher) Mechanisms of Action Defined (Goss, Dietz, Cook)» Inhibition of DA synthesis » Conditional bactericidal activity alidixic Acid released for clinical use for treatment of urinary tract infections caused by enteric bacteria Resistance to alidixic Acid in E. coli mapped to chromosomal mutations (nala,b) (Hane)
6 Quinolones The Second Decade (Adolescence) 1970 Development of Piromidic Acid, the 1st pyrrolindinyl quinolone 1975 Development of Pipemidic Acid, the 1st piperazinyl quinolone 1976 Discovery of DA gyrase, the 1st type 2 topoisomerase (Gellert) 1976 Development of lumequine, the 1st fluoroquinolone and tricyclic quinolone 1977 alidixic Acid resistance loci identified as encoding mutant subunits of DA gyrase of E. coli (Gellert, Cozzarelli)
7 Piromidic Acid lumequine Pipemidic Acid
8 Quinolones - The Third Decade (Adolescent Growth Spurt) 1986 orfloxacin released for clinical use in US (GU infections) 1986 Development of leroxacin, 1st 6, 8- difluoroquinolone (recognition of photosensitivity associated with 8-) 1987 Ciprofloxacin released for clinical use in US (broad indications) Identification of drug resistance by altered permeation for hydrophilic quinolones - active efflux and altered porins
9 H orfloxacin H 3 C O C 2 H 5 leroxacin COOH O H CH 2 CH 2 COOH O COOH Ciprofloxacin
10 Quinolone Phototoxicity UVA ( nm) interactions Generation of reactive oxygen species Drug concentrations in skin SARs Position 8: C-halogen > -H > C-H > C-O-R Position 7: Alkylated rings increase t½ Position 5: CH 3 > H > H 2
11 Quinolones - The ourth Decade (Problems of Adolescence) Ofloxacin PO/IV released for clinical use in US (broad indications) Discovery of Topoisomerase IV (Kato) Enoxacin PO released in US (GU indications) 1992 Temafloxacin released and withdrawn due to unexpected rare but severe toxicities (Hemolytic-Uremic Syndrome) 1992 Lomefloxacin PO released in US, 1st oncedaily fluoroquinolone Identification of quinolone inhibition of topoisomerase IV of E. coli
12 H O H CH 3 Enoxacin O Temafloxacin C 2 H 5 O COOH COOH H 3 C COOH HCl H H 3 C C 2 H 5 Lomefloxacin O COOH * Ofloxacin O CH 3
13 Quinolones - The ourth Decade (Adulthood) Identification of topoisomerase IV as principal quinolone target in S. aureus and secondary target in E. coli Levofloxacin PO/IV and sparfloxacin PO released in US (expanded Gram+ respiratory indications) Grepafloxacin PO (Respiratory/GU Indications) and Trovafloxacin PO/IV (broadest indications, 1st anti-anaerobic quinolone) released in US
14 H 3 C CH 3 O O H Levofloxacin CH 3 O CH 3 COOH CO 2 H H 3 C H 3 C H Grepafloxacin Trovafloxacin H H 2 Sparfloxacin H H 2 O O COOH CO 2 H
15 Quinolones - The ourth Decade (Adults Have Their Ups & Downs) Plasmid transferable quinolone resistance identified Trovafloxacin use restricted due to rare but severe hepatotoxicity (? Legacy of temafloxacin) Grepafloxacin withdrawn because of cardiac events. Sparfloxacin also associated with arrhythmias Gatifloxacin PO/IV and Moxifloxacin PO released with a focus on respiratory tract indications
16 Rare, Serious Idiosyncratic Reactions Temafloxacin (1992) Hemolytic uremic syndrome Coagulopathy (35%) Hepatic dysfunction (51%) Reporting incidence ~1:6000 Trovafloxacin (1999) Symptomatic hepatitis Life-threatening in ~10% Reporting incidence ~1:18,000 Blum MD et al Clin Infect Dis 18:946 Ball P et al Drug Safety 21:407
17 Quinolones - The ourth Decade (Adults Have Their Ups & Downs) Trovafloxacin use restricted due to rare but severe hepatotoxicity (? Legacy of temfloxacin) Grepafloxacin withdrawn because of cardiac events. Sparfloxacin also associated with arrhythmias Gatifloxacin PO/IV and Moxifloxacin PO released with a focus on respiratory tract indications
18 Effects of Drugs on Cardiac Conduction Drug QT C Prolongation I a kr herg IC b 30 (msec) (µm) (µm) Sparfloxacin Grepafloxacin Moxifloxacin Gatifloxacin Terfenidine 46 Erythromycin 8-15 Clarithromycin 2-6 a Anderson et al. 3rd ECC b Chen et al. ICAAC 2000 abstr 765
19 Quinolones - The ourth Decade (Adults Have Their Ups & Downs) Trovafloxacin use restricted due to rare but severe hepatotoxicity (? Legacy of temfloxacin) Grepafloxacin withdrawn because of cardiac events. Sparfloxacin also associated with arrhythmias Gatifloxacin PO/IV and Moxifloxacin PO released with a focus on respiratory tract indications
20 Quinolone Structure-Activity Relationships Domagala JM J Antimicrob Chemother 33:685
21 Quinolone Structure-Adverse Effects Relationships Domagala JM J Antimicrob Chemother 33:685
22 Quinolones - The ifth Decade (Adults Have Their Ups & Downs) Plasmid-encoded Qnr protein identified as protecting gyrase from quinolones Gemifloxacin approved for communityacquired pneumonia with 5-day regimen Plasmid-encoded quinolone-modifying enzyme identified as mutant AAC(6 )-Ib Plasmid-encoded QepA efflux pump identified Gatifloxacin withdrawn because of dysglycemia events
23 2009 irst topoisomerase IV-DA crystal structures with quinolone bound Laponogov I et al. ature Struct Mol Biol. 2009; 16:667
24 The luoroquinolone amily American Branch The Sixth Decade 12 Approvals over 17 Years orfloxacin (oroxin) 1986 Ciprofloxacin (Cipro) 1987 PO, 1990 IV Ofloxacin (loxin) 1990 PO, 1992 IV XXX Enoxacin (Penetrex) 1991 XXX Lomefloxacin (Maxaquin) 1992 Levofloxacin (Levaquin) 1996 XXX Sparfloxacin (Zagam) 1996 Grepafloxacin XXX (Raxar) 1997 Trovafloxacin XXX (Trovan) 1997 Gatifloxacin XXX (Tequin) 1999 Moxifloxacin (Avelox) 1999 Gemifloxacin (active) 2003
25 Adverse Effects of luoroquinolones Gastrointestinal ausea, vomiting, diarrhea Central ervous System Dizziness (trovafloxacin), insomnia, seizures Cardiovascular QT C prolongation (sparfloxacin, grepafloxacin > moxifloxacin) Hepatic Idiosyncratic hepatitis (trovafloxacin) Metabolic Skin Dysglycemia (gatifloxacin > levofloxacin) Photosensitivity (sparfloxacin, lomefloxacin) Other skin reactions (gemifloxacin) Musculoskeletal Tendinopathy
26 Quinolones The Sixth Decade Senescence or ew Generations to ollow The Search Goes On Keys to success: Dealing with established resistance Low potential for new resistance High tolerability (no surprises better preclinical screening tools)
27 Problems With Development of Bacterial Resistance to luoroquinolones Staphylococci (MRSA, MRSE) 60-95% Pseudomonas aeruginosa 5-30% Campylobacter jejuni 3-50% Escherichia coli 8-26% eisseria gonorrheae 6-70% Streptococcus pneumoniae 3%
28 Predicting Resistance Potential: (Which Quinolone Will Live the Longest?) Determinants of bacterial resistance Activity against both target enzymes, DA gyrase and DA topoisomerase IV Effects of native bacterial efflux systems Potency that keeps drug concentrations above the MIC of first-step resistant mutants (mutant prevention concentration)
29 Activity: (Relative to Ciprofloxacin) Sitafloxacin H 2 Pharmacokinetics: Cl O CO 2 H S. pneumoniae Other streptococci Enterococci S. aureus B. fragilis P. aeruginosa (16x) (16-32x) (16x) (>2-32x) (64x) (1-6x) 500mg PO C max 4.6 µg/ml t 1/2 = 4.5-5h; renal (70%) V d = 1.8 liters Anderson DL. Drugs of Today 2008; 44:489.
30 Prulifloxacin/Ulifloxacin Activity: (Relative to Levofloxacin) S. pneumoniae S. pyogenes Enterococci S. aureus Klebsiella spp. Enterobacter spp. P. aeruginosa (1x) (1x) (1x) (1x) (4x) (4x) (0.5-2x) Montanari MP et al. Antimicrob Agents Chemother. 2001; 45:3616
31 inafloxacin Organism MIC (median, μg/ml) ph 5.0 ph 7.3 in Cip in Cip E. coli CipS CipS K. pneumoniae CipS CipS S. aureus CipS CipS th ICAAC, IDSA Abstract
32 Zabofloxacin (DW-224a) MeO H Activity: (Relative to Moxifloxacin) O O OH S. aureus S. pneumoniae a Enterococci K. pneumoniae E. cloacae P. aeruginosa (2-4x) (16x) (4-16x) (1x) (0.5x) (~1x) [ a Advantage maintained vs parc gyra double mutants of S. pneumoniae Serial passage selection: 4-16 x MIC to max of 2 μg/ml] Park H-S et al. Antimicrob Agents Chemother. 2006; 50:2261 Kosowska-Shick K et al. Antimicrob Agents Chemother. 2006; 50:2064
33 Delafloxacin (RX-3341, ABT492) Activity: (Relative to Levofloxacin) S. aureus MRSA S. aureus MSSA Enterococci S. pyogenes S.epidermidis S. pneumoniae H. influenzae L. pneumophila Chlamydia spp. K. pneumoniae M. pneumoniae P. aeruginosa >64x >64x 16x >64x 32x 128x 16-32x 8x 2-32x 4x 2x 0.5-1x
34 WCK-771 (S-nadifloxacin) Activity: (Relative to Levofloxacin) Pharmacokinetics: S. pneumoniae S. pyogenes S. aureus a S. epidermidis ( 2x) (2x) (16-32x) (16-32x) 600mg IV C max 4.0 µg/ml t 1/2 = 6 h [ a irst-step selection: S. aureus mutations in gyra with 2x MIC] Jacobs MR et al. Antimicrob Agents Chemother 2004; 48:3338 Al-Laham A et al. J Antimicrob Chemother 2005; 56:1130 Bhagwat SS et al. Antimicrob Agents Chemother. 2006; 50:3568
35 H 2 Activity: (Relative to Levofloxacin) Pharmacokinetics: DX-619 OMe O O OH S. pneumoniae ( 128x) Other streptococci (32-64x) Enterococci (64x) S. aureus a (16-128x) Klebsiella spp. (1x) P. aeruginosa (2x) Lung:serum ratio 5.3 (3x > cipro) in mice ujikawa K et al. Antimicrob Agents Chemother. 2005; 49:3040 Wickman PA et al. Antimicrob Agents Chemother. 2006; 50:2255 ukuda Y et al. Antimicrob Agents Chemother. 2006; 50:121
36 Activity: (Relative to Levofloxacin) DC-159a S. pneumoniae Enterococci S. aureus H. influenzae Peptostreptococcus B. fragilis K. pneumoniae P. aeruginosa (8-32x) (8x) (4-16x) (1x) (32x) (16x) (1x) (0.5x) Hoshino K et al. Antimicrob Agents Chemother. 2008; 52:65
37 PD and PD Activity: (Relative to Levofloxacin) S. aureus S. pneumoniae a Enterococci S. pyogenes K. pneumoniae E. cloacae (2-32x) (16-32x) (128x) (64x) (0.12x) (0.25x) [ a irst-step mutants in gyrb (2x MIC) or gyrb pare (4x MIC)] Efficacy > levofloxacin in murine pneumococcal pneumonia model Huband MD et al. Antimicrob Agents Chemother. 2007; 51:1191
38 Activity: (Relative to Levofloxacin) ACH-702 S. aureus a (>32->64x) S. pneumoniae (16x) Enterococci (>8->32x) S. pyogenes (16x) K. pneumoniae (2x) Enterobacter spp. (0.25-1x) P. aeruginosa (0.5x) [MIC 90 : B. fragilis 0.25 μg/ml, Peptostreptococcus 0.06 μg/ml] [ a Single-step gyra mutants with 4x MIC] 48 th ICAAC, IDSA Abstract ,
39 Long Life Sometimes eeds Help from the Doctor(s) Monitoring resistance Good Infection Control to Limit Spread ocused Use to Limit Selective Pressures Adequate Dosing to Limit Mutant Selection Possible Use of Combination Regimens: With Other Antibiotics Specific Inhibitors of Resistance Mechanisms
Appropriate Use of Quinolones in the Hospital: Is Microbiology Telling You All?
Appropriate Use of Quinolones in the Hospital: Is Microbiology Telling You All? David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical
More informationFluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do?
Fluoroquinolones in 2007: the Angels, the Devils, and What Should the Clinician Do? David C. Hooper, M.D. Division of Infectious Diseases Infection Control Unit Massachusetts General Hospital Harvard Medical
More information2 key enzymes in DNA replication:
Mechanism of action of fluoroquinolones: the basics... PRI DA DA gyrase Topo isomerase Gram (-) Gram (+) 1 2 key enzymes in DA replication: DA gyrase topoisomerase IV bacterial DA is supercoiled 2 1 Ternary
More informationChoosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections
...CLINICIAN INTERVIEW... Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections An interview with Robert C. Owens, Jr., PharmD, Clinical Pharmacy
More informationMechanism of action of fluoroquinolones: the basics...
Mechanism of action of fluoroquinolones: the basics... PRI DA DA gyrase Topo isomerase Gram (-) Gram (+) 1 2 key enzymes in DA replication: DA gyrase topoisomerase IV bacterial DA is supercoiled 2 Ternary
More information2 key enzymes in DNA replication:
Mechanism of action of fluoroquinolones: the basics... PRI DA DA gyrase Topo isomerase Gram (-) Gram (+) 1 2 key enzymes in DA replication: DA gyrase topoisomerase IV bacterial DA is supercoiled 2 1 Ternary
More informationPinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu
Search for: Search Search Does levaquin cover anaerobes Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Levofloxacin, sold under the trade names Levaquin among others, is an antibiotic.
More informationThe Newer Fluoroquinolones
The Newer Fluoroquinolones Maureen K. Bolon, MD, MS KEYWORDS Fluoroquinolones Antiinfective agents Pharmacology Pharmacokinetics Microbial drug resistance Therapeutic use Quinolones are unusual among antimicrobials
More informationChapter 46. Sulfonamides, Trimethoprim, & Quinolones
Chapter 46 Sulfonamides, Trimethoprim, & Quinolones Classification of synthetic antimicrobial agents Ⅰ. Antifolate drugs: a. Sulfonamides b. Trimethoprim Ⅱ. DNA gyrase inhibitors: Fluoroquinolones Ⅰ. Antifolate
More informationAdvances in Fluoroquinolones Therapy
Advances in Fluoroquinolones Therapy Fluoroquinolones Synthetic antimicrobial agents with the characteristic 4- quinolone ring structure containing a fluorine moiety at the 6-position. Some members also
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationCLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES THE AMINOGLYCOSIDES:
CLINICAL USE OF AMINOGLYCOSIDES AND FLUOROQUINOLONES Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu THE AMINOGLYCOSIDES: 1944-1975 Drug
More informationBacterial Resistance of Respiratory Pathogens. John C. Rotschafer, Pharm.D. University of Minnesota
Bacterial Resistance of Respiratory Pathogens John C. Rotschafer, Pharm.D. University of Minnesota Antibiotic Misuse ~150 million courses of antibiotic prescribed by office based prescribers Estimated
More informationDevelopment of Resistant Bacteria Isolated from Dogs with Otitis Externa or Urinary Tract Infections after Exposure to Enrofloxacin In Vitro
A. M. Brothers, P. S. Gibbs, and R. E. Wooley Development of Resistant Bacteria Isolated from Dogs with Otitis Externa or Urinary Tract Infections after Exposure to Enrofloxacin In Vitro Amy M. Brothers,
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationJournal of Antimicrobial Chemotherapy Advance Access published August 26, 2006
Journal of Antimicrobial Chemotherapy Advance Access published August, Journal of Antimicrobial Chemotherapy doi:./jac/dkl Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae,
More informationAZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES
AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES Update in Medicine and Primary Care Whitney R. Buckel, PharmD, BCPS-AQ ID System Antimicrobial Stewardship Pharmacist Manager OBJECTIVES 1. List three antibiotics
More informationAminoglycosides. Spectrum includes many aerobic Gram-negative and some Gram-positive bacteria.
Aminoglycosides The only bactericidal protein synthesis inhibitors. They bind to the ribosomal 30S subunit. Inhibit initiation of peptide synthesis and cause misreading of the genetic code. Streptomycin
More informationCommunity Acquired Pneumonia: An Update on Guidelines
Community Acquired Pneumonia: An Update on Guidelines Claudia Summa, BScPhm Pharmacy Resident September 12, 2006 Objectives To give a brief description of the pathophysiology of community acquired pneumonia
More informationORIGINAL ARTICLE /j x. Western Reserve University, Cleveland, OH, USA and 3 Wockhardt Research Centre, Aurangabad, India
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01017.x Activity of the new quinolone WCK 771 against pneumococci P. C. Appelbaum 1, G. A. Pankuch 1, B. Bozdogan 1, G. Lin 1, M. R. Jacobs 2, M. V. Patel 3, S.
More informationnumber Done by Corrected by Doctor Dr Hamed Al-Zoubi
number 8 Done by Corrected by Doctor Dr Hamed Al-Zoubi 25 10/10/2017 Antibacterial therapy 2 د. حامد الزعبي Dr Hamed Al-Zoubi Antibacterial therapy Figure 2/ Antibiotics target Inhibition of microbial
More informationWARNING: CERTAIN ANTIBIOTICS MAY CAUSE PERMANENT NERVE DAMAGE
WARNING: CERTAIN ANTIBIOTICS MAY CAUSE PERMANENT NERVE DAMAGE By Dr. Michael John Badanek, BS, DC, CNS, CTTP, DACBN, DCBCN, MSGR./CHEV In the past 36 plus years of clinical practice of Integrative/Functional
More informationREVIEW ARTICLE. Quinolones in 2005: an update F. Van Bambeke 1, J.-M. Michot 1, J. Van Eldere 2 and P. M. Tulkens /j
REVIEW ARTICLE 10.1111/j.1469-0691.2005.01131.x Quinolones in 2005: an update F. Van Bambeke 1, J.-M. Michot 1, J. Van Eldere 2 and P. M. Tulkens 1 1 Unit of Cellular and Molecular Pharmacology, Catholic
More informationChristine E. Thorburn and David I. Edwards*
Journal of Antimicrobial Chemotherapy (2001) 48, 15 22 JAC The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence
More informationDoes the Dose Matter?
SUPPLEMENT ARTICLE Does the Dose Matter? William A. Craig Department of Medicine, University of Wisconsin, Madison, Wisconsin Pharmacokinetic/pharmacodynamic (PK/PD) parameters, such as the ratio of peak
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationAntibiotics & treatment of Acute Bcterial Sinusitis. Walid Reda Product Manager. Do your antimicrobial options meet your needs?
Antibiotics & treatment of Acute Bcterial Sinusitis Walid Reda Product Manager Do your antimicrobial options meet your needs? Antimicrobial Effects: What s involved? Effect in Humans: Serum concentration
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Key Points Early and rapid diagnosis of infection and prompt initiation of appropriate antimicrobial therapy, if warranted, are fundamental to reducing the mortality
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More informationfolate-derived cofactors purines pyrimidines Sulfonamides sulfa drugs Trimethoprim infecting bacterium to perform DNA synthesis cotrimoxazole
Folate Antagonists Enzymes requiring folate-derived cofactors are essential for the synthesis of purines and pyrimidines (precursors of RNA and DNA) and other compounds necessary for cellular growth and
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationCan levaquin treat group b strep
Can levaquin treat group b strep The Borg System is 100 % Can levaquin treat group b strep IBS - Symptoms, Diet and Treatment. IBS, is the common slang term or abbreviation for Irritable Bowel Syndrome
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationQuinolones. Drugs: norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin Mechanism of action:
Quinolones Drugs: norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin Mechanism of action: Inhibit bacterial DNA synthesis by inhibiting DNA gyrase and topoisomerase IV rapid cell death Post
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationMedicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!
Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which
More informationCipro for gram positive cocci in urine
Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar
More information3/9/15. Disclosures. Salmonella and Fluoroquinolones: Where are we now? Salmonella Current Taxonomy. Salmonella spp.
Salmonella and Fluoroquinolones: Where are we now? Eszter Deak, PhD, D(ABMM) Chief, Clinical Microbiology Santa Clara Valley Medical Center San Jose, CA Eszter.Deak@hhs.sccgov.org Disclosures Nothing to
More informationFluoroquinolones Cross reaction. Suluck Soontaros Chonburi Hospital
Fluoroquinolones Cross reaction Suluck Soontaros Chonburi Hospital Quinolones generation Frist Second Third Fourth drug Non-fluorinated drug; nalidixic acid Norfloxacin, Ofloxacin, Ciprofloxacin Levofloxacin
More informationAnimal models and PK/PD. Examples with selected antibiotics
Animal models and PK/PD PD Examples with selected antibiotics Examples of animal models Amoxicillin Amoxicillin-clavulanate Macrolides Quinolones Andes D, Craig WA. AAC 199, :375 Amoxicillin in mouse thigh
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationProtein Synthesis Inhibitors
Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors
More informationPK/PD to fight resistance
PK/PD to fight resistance Eradicate Abnormal bacteria Mutations Efflux pumps Mutation-Preventing Concentration Breakpoint values for T > MIC and in practice With the support of Wallonie-Bruxelles-International
More informationMARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS
MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT MARBOCYL FD 1 %, powder and solvent for solution for injection, for cats and dogs. 2. QUALITATIVE AND QUANTITATIVE
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationArchive entry. Content:
Archive entry Content: 1. Basic information about Moxifloxacin 2. History of quinolone-drugs 3. Structure of Moxifloxacin 4. 3D-structure of Moxifloxacin 5. Synthesis of Moxifloxacin 6. Biological function
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More informationAdvanced Practice Education Associates. Antibiotics
Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationCommunity-Acquired Pneumonia (CAP)
Community-Acquired Pneumonia (CAP) Infectious Diseases Advisory Board 14/01/2000 - Woluwé St Lambert Colloquium Longartsen - 11/02/2000 Dr Yvan Valcke Belgian guidelines on the initial diagnostic and therapeutic
More informationAntimicrobial Safety: Focus on Fluoroquinolones
SUPPLEMENT ARTICLE Antimicrobial Safety: Focus on Fluoroquinolones Robert C. Owens, Jr. 1,2 and Paul G. Ambrose 3 1 Antimicrobial Stewardship Program, Department of Clinical Pharmacy Services and Division
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationComparative Study of the Mutant Prevention Concentration of Moxifloxacin, Levofloxacin and Gemifloxacin against Pneumococci.
AAC Accepts, published online ahead of print on 14 December 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.01353-09 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationCipro and the aorta Fluoroquinolone attack? Bulat A. Ziganshin, MD, PhD and John A. Elefteriades, MD, PhD (hon)
Cipro and the aorta Fluoroquinolone attack? Bulat A. Ziganshin, MD, PhD and John A. Elefteriades, MD, PhD (hon) Aortic Institute at Yale-New Haven, Yale University School of Medicine New Haven, Connecticut,
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationAntimicrobial Therapy
Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the
More informationWHY IS THIS IMPORTANT?
CHAPTER 20 ANTIBIOTIC RESISTANCE WHY IS THIS IMPORTANT? The most important problem associated with infectious disease today is the rapid development of resistance to antibiotics It will force us to change
More information3/23/2017. Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc. Kathryn G. Smith: Nothing to disclose
Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc Kathryn G. Smith: Nothing to disclose Describe the new updates and rationale for them Relay safety concerns with use of
More informationOutpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Acute Bacterial Rhinosinusitis
Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment
More informationETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae
ETX0282, a Novel Oral Agent Against Multidrug-Resistant Enterobacteriaceae Thomas Durand-Réville 02 June 2017 - ASM Microbe 2017 (Session #113) Disclosures Thomas Durand-Réville: Full-time Employee; Self;
More informationEUCAST Expert Rules for Staphylococcus spp IF resistant to isoxazolylpenicillins
EUAST Expert Rules for 2018 Organisms Agents tested Agents affected Rule aureus Oxacillin efoxitin (disk diffusion), detection of meca or mec gene or of PBP2a All β-lactams except those specifically licensed
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationThe new fluoroquinolones: A critical review
REVIEW The new fluoroquinolones: A critical review George G Zhanel PharmD PhD 1,3,5,6, Andrew Walkty BSc Pharm 6, Lavern Vercaigne PharmD 4,6, James A Karlowsky PhD 1,5,6, John Embil MD 2,5, Alfred S Gin
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationTopical Antibiotic Update. Brad Sutton, O.D., F.A.A.O. Indiana University School of Optometry Indianapolis Eye Care Center No financial disclosures
Topical Antibiotic Update Brad Sutton, O.D., F.A.A.O. Indiana University School of Optometry Indianapolis Eye Care Center No financial disclosures What do we have? We currently have many highly effective
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم 1.lincomycin and clindamycin: Continuously with those agents which usually act by inhibiting microbial protein synthesis which step is involved it is not at this level offered and
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationLifting the lid off CAP guidelines
Lifting the lid off CAP guidelines Dr. Andrew M. Morris September 5, 2007 12:00-13:00 web.mac.com/idologist Objectives 1. To review the epidemiology of community-acquired pneumonia (CAP) 2. To explore
More informationDevelopment of the quinolones
Journal of Antimicrobial Chemotherapy (2003) 51, Suppl. S1, 1 11 DOI: 10.1093/jac/dkg212 Development of the quinolones Monique I. Andersson and Alasdair P. MacGowan* Bristol Centre for Antimicrobial Research
More informationAntibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017
Antibiotics Antimicrobial Drugs Chapter 20 BIO 220 Antibiotics are compounds produced by fungi or bacteria that inhibit or kill competing microbial species Antimicrobial drugs must display selective toxicity,
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Marbotab P 20 mg tablets for dogs and cats
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Marbotab P 20 mg tablets for dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:
More informationResistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints
...PRESENTATIONS... Resistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints Angela B. Brueggemann, MS; and Gary V. Doern, PhD Presentation Summary Streptococcus pneumoniae
More informationACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role
More informationPharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANT/ MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES Marketing Member State Authorisation
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationOutpatient Antimicrobial Therapy. Role of Antibacterials in Outpatient Treatment of Respiratory Tract Infection. Acute Bacterial Rhinosinusitis
Outpatient Antimicrobial Therapy B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy University of California San Francisco Role of Antibacterials in Outpatient Treatment
More informationLefamulin: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM
: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM Department of Critical Care, University Hospital ATTIKON National and Kapodistrian University of Athens, Medical School
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationCME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Boflox flavour 20 mg tablets for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance:
More informationWhat Have We Learned from Pharmacokinetic and Pharmacodynamic Theories?
SUPPLEMENT ARTICLE PHARMACOLOGY What Have We Learned from Pharmacokinetic and Pharmacodynamic Theories? Jerome J. Schentag, Kristin K. Gilliland, and Joseph A. Paladino State University of New York at
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationAlasdair P. MacGowan,* Chris A. Rogers, H. Alan Holt, and Karen E. Bowker
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 2003, p. 1088 1095 Vol. 47, No. 3 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.3.1088 1095.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationSummary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Enrotab 50 mg tablets for dogs
Summary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrotab 50 mg tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance Enrofloxacin
More informationSAR (structure-activity relationship) in tossicologia
SAR (structure-activity relationship) in tossicologia L esempio dei fluorochinoloni Wednesday, December 14, 11 Asian Journal of Andrology (2011) 13, 819 827 ß 2011 AJA, SIMM & SJTU. All rights reserved
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationIntroduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018
Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More information1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Summary of Prodcuct Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Enrox Max 100 mg/ml Solution for Injection for Cattle and Pigs Enroxal Max 100 mg/ml Solution for Injection for Cattle and
More information